Predictivity of early and late assessment for post-surgical recurrence of Crohn's disease: Data from a single-center retrospective series.


Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 12 07 2020
revised: 20 09 2020
accepted: 21 09 2020
pubmed: 3 2 2021
medline: 3 2 2022
entrez: 2 2 2021
Statut: ppublish

Résumé

Post-surgical recurrence of Crohn's disease (CD) after ileocolonic resection is common. Early identification of features associated with recurrence is a standard procedure of postoperative management, but the prognostic role of such features when detected at later time points is unclear. We compared the predictivity for Crohn's disease recurrence of common clinical-instrumental variables when assessed early (<12 months) or late (>36 months) after surgery. This retrospective study considered CD patients who had ileocolonic resection and were followed for a median of 7.6 years. Clinical characteristics, post-surgical therapy, endoscopy recurrence (Rutgeerts' score ≥i2) and ultrasound features were compared between subgroups who had a early or late post-surgical assessment. Univariate and multivariate analyses were done to identify variables associated with recurrence (clinical and surgical). Of 201 patients, 70 (32%) had a early and 39 (19%) had a late post-surgical assessment. The Early and Late subgroups had similar clinical characteristics. Overall, clinical relapse was observed in 131 patients (66%), surgical relapse in 31 (16%), endoscopic recurrence in 149 (75%) and ultrasonographic recurrence in 132 (66%), without significant differences in frequencies between subgroups. By Cox proportional hazard regression, endoscopic recurrence was a significant predictor of clinical recurrence overall (HR=2.31, P = 0.002) and in the Early (HR=3.85, P = 0.002) but not Late subgroup. The most informative postoperative CD assessment is the one done within the first year of surgery. Later endoscopic evaluations have no prognostic value and should be done only for clinical needs or for research purposes.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Post-surgical recurrence of Crohn's disease (CD) after ileocolonic resection is common. Early identification of features associated with recurrence is a standard procedure of postoperative management, but the prognostic role of such features when detected at later time points is unclear. We compared the predictivity for Crohn's disease recurrence of common clinical-instrumental variables when assessed early (<12 months) or late (>36 months) after surgery.
METHODS METHODS
This retrospective study considered CD patients who had ileocolonic resection and were followed for a median of 7.6 years. Clinical characteristics, post-surgical therapy, endoscopy recurrence (Rutgeerts' score ≥i2) and ultrasound features were compared between subgroups who had a early or late post-surgical assessment. Univariate and multivariate analyses were done to identify variables associated with recurrence (clinical and surgical).
RESULTS RESULTS
Of 201 patients, 70 (32%) had a early and 39 (19%) had a late post-surgical assessment. The Early and Late subgroups had similar clinical characteristics. Overall, clinical relapse was observed in 131 patients (66%), surgical relapse in 31 (16%), endoscopic recurrence in 149 (75%) and ultrasonographic recurrence in 132 (66%), without significant differences in frequencies between subgroups. By Cox proportional hazard regression, endoscopic recurrence was a significant predictor of clinical recurrence overall (HR=2.31, P = 0.002) and in the Early (HR=3.85, P = 0.002) but not Late subgroup.
DISCUSSION CONCLUSIONS
The most informative postoperative CD assessment is the one done within the first year of surgery. Later endoscopic evaluations have no prognostic value and should be done only for clinical needs or for research purposes.

Identifiants

pubmed: 33526411
pii: S1590-8658(20)30917-8
doi: 10.1016/j.dld.2020.09.018
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

987-995

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest GDP, MM, MM, CR, PM, MC, CR, EM, EE, AL, RR, AF: reported no conflict of interest to disclose CG: Roche boards MD: Advisory board/Lecturer/Grants/Congress participation from Abbvie, Takeda, Janssen, Ferring, MSD, Mundipharma, Pfizer, SOFAR, Chiesi, Roche, Bioclinica

Auteurs

Giulia Dal Piaz (G)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy; Gastroenterology Unit, Alessandria Hospital, Alessandria, Italy.

Marco Mendolaro (M)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy; Gastroenterology Unit, San Luigi Gonzaga Hospital, Orbassano, Italy.

Michela Mineccia (M)

Surgery Unit, Mauriziano Hospital, Turin, Italy.

Claudia Randazzo (C)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy; Studio Medico Randazzo, Palermo, Italy.

Paolo Massucco (P)

Surgery Unit, Mauriziano Hospital, Turin, Italy.

Maurizio Cosimato (M)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy.

Caterina Rigazio (C)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy; Gastroenterology Unit, Regina Margherita Pediatric Hospital, Turin, Italy.

Cristina Guiotto (C)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy; Laboratory Unit, Mauriziano Hospital, Turin, Italy.

Enrico Morello (E)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy.

Elena Ercole (E)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy.

Alessandro Lavagna (A)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy.

Rodolfo Rocca (R)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy.

Alessandro Ferrero (A)

Surgery Unit, Mauriziano Hospital, Turin, Italy.

Marco Daperno (M)

Gastroenterology Unit, Mauriziano Hospital, Largo Turati 62, I-10128 Turin, Italy. Electronic address: mdaperno@teletu.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH